A Comparison between Moderate- and High-dose Furazolidone in Triple Regimens for Helicobacter pylori Eradication in Iran.

BACKGROUND Furazolidone has been used as an alternative for clarithromycin or metronidazole in Helicobacter pylori (H.pylori) eradication regimens. In Iran, 14-day Furazolidone-containing quadruple regimens have shown promising eradication rates, but short-course, low dose therapies are always attra...

Descripción completa

Detalles Bibliográficos
Publicado en:Middle East Journal of Digestive Diseases Vol. 6; no. 4; pp. 1 - 9
Autores principales: Hosseini, Vahid, Mokhtare, Marjan, Gholami, Mohsen, Taghvaei, Tarang, Maleki, Iradj, Valizadeh, Mohammad, Bari, Zohreh, Fakheri, Hafez
Formato: equations & formulas research tables/charts randomized controlled trial Journal Article
Publicado: Iranian Association of Gastroenterology & Hepatology 2014
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=97921977&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 97921977
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20085230
        BG4K
      jtl: Middle East Journal of Digestive Diseases
      issn: 20085230
      maglogo: N
    pubinfo:
      dt: 2014
      vid: 6
      iid: 4
      pid: 70725
      pub: Iranian Association of Gastroenterology & Hepatology
    artinfo:
      ui:
        97921977
        97921977
        103889698
        97921977
      ppf: 1
      ppct: 8
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: A Comparison between Moderate- and High-dose Furazolidone in Triple Regimens for Helicobacter pylori Eradication in Iran.
      aug:
        au:
          Hosseini, Vahid
          Mokhtare, Marjan
          Gholami, Mohsen
          Taghvaei, Tarang
          Maleki, Iradj
          Valizadeh, Mohammad
          Bari, Zohreh
          Fakheri, Hafez
        affil: Inflammatory Diseases of the Upper Gastrointestinal Tract Research Center, Mazandaran University of Medical Sciences, Sari, Iran
      sug:
        subj:
          Nitrofurans Classification
          Helicobacter Infections Drug Therapy
          Helicobacter Infections Prevention and Control
          Disease Eradication Evaluation
          Human
          Comparative Studies
          Iran
          Helicobacter Pylori
          Randomized Controlled Trials
          Data Analysis Software
          Chi Square Test
      ab: BACKGROUND Furazolidone has been used as an alternative for clarithromycin or metronidazole in Helicobacter pylori (H.pylori) eradication regimens. In Iran, 14-day Furazolidone-containing quadruple regimens have shown promising eradication rates, but short-course, low dose therapies are always attractive. Therefore, we designed a study to compare the efficacy of two 10-day triple regimens containing moderate and high dose furazolidone for H.pylori eradication. METHODS Two hundred and ten patients with peptic ulcer disease who were naïve to H.pylori treatment were included. They were randomized into 2 groups: 105 patients received omeprazole 20mg, amoxicillin 1000mg, and furazolidone 200mg(OAF-400), all twice a day for ten days. And the remaining 105 patients received omeprazole 20mg twice a day, amoxicillin 1000mg twice a day and furazolidone 200mg three times a day for ten days(OAF-600). Urease breath test was performed 8 weeks after the treatment to confirm H. pylori eradication. RESULTS The intention-to-treat eradication rate was 76.19% in group OAF-400 and 80.95% in group OAF-600 (p=0.38). Per protocol eradication rates were 81.63% and 89.47%, respectively (p= 0.11).Severe adverse effects were reported by 8.6% of the patients in group OAF-400 and 5.7% of the patient in group OAF-600 (p=0.1). However, the total side effects (including mild, moderate, and severe ones) were significantly more prevalent in the OAF-600 group (p=0.001). CONCLUSION None of our triple furazolidone-based regimens (moderate- and high-dose) could achieve the standard eradication rate, and therefore, cannot be considered as a suitable option for first-line treatment.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N